AVGR
Avinger Inc.
Healthcare•Medical Devices
Watchlist:
Last updated: Saturday 15th February 2025
0.00
No Change
Prev Close:N/A
Open:0.5561
Bid:N/A
Ask:0.475
52 Week Range
0.000.00
Volume:0
Mkt Cap:0 M
Financials
Financial Statements
AVGR - Income Statement (Annual)
Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Invalid date | |
---|---|---|---|---|---|---|---|---|---|---|
Accretion On Preferred Stock | -5 M | |||||||||
Accrued Preferred Stock Dividends | 5 M | 4 M | 4 M | 4 M | 8 M | 2 M | ||||
Basic EPS From Continuing Operations | -23.31 | -65.4 | -68.55 | -138.0 | ||||||
Basic EPS Total | -23.31 | -65.4 | -68.55 | -138.0 | ||||||
Basic Weighted Shares Outstanding | 786000.0 | 416600.0 | 314800.0 | 164103.0 | 482600.0 | 712466.0 | 43466.0 | 828700.0 | 568100.0 | |
Cost Of Sales | 6 M | 6 M | 7 M | 6 M | -6 M | -7 M | -13 M | -14 M | -6 M | |
Depreciation | 289000.0 | 196000.0 | 687000.0 | 897000.0 | -890000.0 | -934000.0 | -1 M | -2 M | ||
Depreciation And Amortization | 289000.0 | 196000.0 | 687000.0 | 897000.0 | -890000.0 | -934000.0 | -1 M | -2 M | ||
Development Expense | 6 M | |||||||||
Diluted EPS Total | -23.31 | -65.4 | -68.55 | -138.0 | -47.7 | -50.1 | -1121.1 | -67.8 | -87.6 | |
Diluted Weighted Shares Outstanding | 786000.0 | 416600.0 | 314800.0 | 164103.0 | 407756.0 | 550059.0 | 43468.0 | 827846.0 | 540456.0 | |
Excise Taxes | 7 M | |||||||||
General And Administrative Expense | 14 M | 14 M | 16 M | 14 M | -1 M | -2 M | -2 M | -1 M | -938000.0 | |
Gross Operating Profit | 2 M | 3 M | 3 M | 3 M | 3 M | 1 M | -3 M | 5 M | 4 M | |
Income Before Tax | -18 M | -18 M | -17 M | -19 M | -19 M | -28 M | -49 M | -56 M | -47 M | |
Income Restructuring And M&A | 1 M | |||||||||
Income Taxes | -916000.0 | -711000.0 | -760000.0 | 1 M | -2 M | 22000.0 | ||||
Interest Income | 3000.0 | 34000.0 | 288000.0 | 214000.0 | 108000.0 | 125000.0 | 40000.0 | |||
Interest Expense Non Operating | 2 M | 2 M | 2 M | 2 M | 1 M | 6 M | 6 M | 6 M | 5 M | |
Interest Expense Operating | 6 M | |||||||||
Misc Other Special Charges | 34000.0 | -1000.0 | 2 M | 56000.0 | 10 M | 9 M | 10 M | -12000.0 | -2 M | |
Net Income From Total Operations | -18 M | -18 M | -17 M | -19 M | -19 M | -28 M | -49 M | -56 M | -47 M | |
Net Income Common Stockholders | -18 M | -27 M | -22 M | -23 M | -23 M | -36 M | -49 M | -56 M | -50 M | |
Net Income Continuous Operations | -18 M | -18 M | -17 M | -19 M | -19 M | -28 M | -49 M | -56 M | -47 M | |
Net Non Operating Interest Income Expense | -2 M | -2 M | -2 M | -2 M | -1 M | -5 M | -6 M | -5 M | -5 M | |
Non Recurring Operation Expense | 2 M | |||||||||
Normalized Income | -9 M | |||||||||
Operating Income | -17 M | -16 M | -18 M | -17 M | -28 M | -31 M | -49 M | -51 M | -41 M | |
Operating Income Before Depreciation (EBITDA) | -16 M | -16 M | -17 M | -16 M | -17 M | -20 M | -41 M | -49 M | -41 M | |
Operating Expense | 19 M | 19 M | 22 M | 20 M | -22 M | -24 M | -39 M | -55 M | -45 M | |
Other Income Net | 34000.0 | -1000.0 | -2 M | -56000.0 | -10 M | -9 M | -10 M | 12000.0 | 2 M | |
Other Gand A | 14 M | 14 M | 16 M | 14 M | -1 M | -2 M | -2 M | -1 M | -938000.0 | |
Other Operating Expenses | -216000.0 | -203000.0 | -228000.0 | -169000.0 | -177000.0 | -120000.0 | -211000.0 | -55 M | -45 M | |
Otherunder Preferred Stock Dividend | -601000.0 | 4 M | 4 M | 4 M | 8 M | 2 M | ||||
Preferred Stock Dividends | -601000.0 | 4 M | 4 M | 4 M | 8 M | 2 M | ||||
Promotion And Advertising | -101000.0 | -526000.0 | ||||||||
Rent And Landing Fees | -2 M | -1 M | -938000.0 | |||||||
Research & Development Expense | 5 M | 10 M | 6 M | 6 M | 6 M | 6 M | 11 M | 16 M | 16 M | |
Research Expense | 5 M | 4 M | 6 M | 6 M | 6 M | 6 M | 11 M | 16 M | 16 M | |
Restructring And Mn A Income | 1 M | |||||||||
Revenue Per Share | 1 M | 1 M | 1000000.0 | 964000.0 | -676000.0 | -9000.0 | -11000.0 | |||
Salaries And Wages | -2 M | -3 M | -5 M | -7 M | ||||||
Selling Gen & Administrative Expense | 14 M | 14 M | 16 M | 14 M | 17 M | 18 M | 25 M | 40 M | 29 M | |
Selling And Marketing Expense | 7 M | 17 M | 18 M | 25 M | 40 M | 29 M | ||||
Selling Expense | 7 M | 17 M | 18 M | 25 M | 40 M | 29 M | ||||
Special Income/charges | -6 M | -3 M | ||||||||
Total Income Available For Interest Expense (EBIT) | -17 M | -16 M | -18 M | -11 M | -18 M | -22 M | -42 M | -51 M | -42 M | |
Total Common Shares Outstanding | 2 M | 574300.0 | 361918.0 | 317660.0 | 56044.0 | 14099.0 | 1461.0 | 2989.0 | 1586.0 | |
Total Net Income | -18 M | -18 M | -17 M | -19 M | -19 M | -28 M | -49 M | -56 M | -47 M | |
Total Ordinary Shares | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | |
Total Revenues | 8 M | 8 M | 10 M | 9 M | 9 M | 8 M | 10 M | 19 M | 11 M | |
Total Expenses | 24 M | 24 M | 28 M | 26 M | -28 M | -31 M | -52 M | -70 M | -51 M | |
Total Revenue | 8 M | 8 M | 10 M | 9 M | 9 M | 8 M | 10 M | 19 M | 11 M | |
Write Off | 6 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.